Alex Menzies
Melanoma Institute Australia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alex Menzies as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02645149 · Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic MelanomaMelanoma Institute Australia · completed · Melanoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:46 UTC. The ranking covers the 200 most relevant of 44 PubMed records, and a shared surname and initials can bring in a namesake. All 44 on PubMed
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.Lancet Oncol · 2018815 citationsRCR 26.8
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.N Engl J Med · 2024480 citationsRCR 53.1
- 467 citationsRCR 15.0
- 334 citationsRCR 20.4
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.J Clin Oncol · 2019325 citationsRCR 10.9
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.Nat Med · 2021300 citationsRCR 13.4
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.Nat Med · 2023205 citationsRCR 17.8
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.Lancet Oncol · 2017190 citationsRCR 5.5
- 164 citationsRCR 4.9
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).J Clin Oncol · 2023154 citationsRCR 10.8